Biogen Idec Inc
Mar 13, 2010 at 14:12 | Source: Reuters
Photos »
/ 
Interact & exchange stock tips & market info »
Related News »
Biogen Idec Inc. (Biogen) is a leading biotechnology company focusing on the development, manufacturing and commercialization of therapies used in the areas of oncology, neurology, immunology and cardiology. It offers products to address diseases such as ...
May 13, 2012 at 13:55 | Source: Transworld News
Biogen Idec (NASDAQ: BIIB) announced that two new dosing innovations designed to help patients receiving once-a-week AVONEX (interferon beta-1a) for relapsing forms of multiple sclerosis (MS) are now available in U.S. pharmacies: The new AVONEX PEN (AVONEX ...
May 15, 2012 at 03:37 | Source: 4-traders (press release)
Biogen Idec Inc. develops, manufactures, and commercializes therapies, focusing on neurology, oncology, and immunology. The Company's products addresses diseases such as multiple sclerosis, non-Hodgkin's lymphoma, rheumatoid arthritis ...
May 23, 2012 at 14:47 | Source: TMCnet
Biogen Idec Inc. develops, manufactures, and commercializes therapies, focusing on neurology, oncology, and immunology. The Company's products addresses diseases such as multiple sclerosis, non-Hodgkin's lymphoma, rheumatoid arthritis, crohn's disease ...
May 18, 2012 at 20:15 | Source: Financial News Network Online
The use of predictive biomarkers will also be explored. AVEO and Biogen Idec International GmbH, a subsidiary of Biogen Idec Inc. ( BIIB), have a strategic alliance to develop and commercialize ERBB3 antibodies for the treatment of cancer. AV-203 is a ...
May 24, 2012 at 22:38 | Source: NASDAQ
"TYSABRI has benefited thousands of patients worldwide who are living with multiple sclerosis, an often devastating disease affecting people in the prime of their lives," said Paul Petrelli , General Manager, Biogen Idec Canada Inc. "Biogen Idec ...
May 23, 2012 at 13:14 | Source: Yahoo Finance
May 26, 2012 (Zacks.com via COMTEX News Network) -- Biogen Idec (BIIB) recently announced that Health ... Teva Pharmaceutical Industries Limited's (TEVA) Copaxone, Pfizer Inc. (PFE)/Serono's Rebif and Novartis' (NVS) Extavia.
May 26, 2012 at 08:17 | Source: comcast.net
Our “non-GAAP net income attributable to Biogen Idec Inc.” and “non-GAAP diluted EPS” financial measures exclude the following items from GAAP net income attributable to Biogen Idec Inc. and diluted EPS: 1. Purchase accounting and merger ...
May 1, 2012 at 10:56 | Source: Boston Globe
Should the shares continue to rise, the resistance pivots of $138.40 and $139.98 will be of interest. Biogen Idec Inc. develops, manufactures, and commercializes therapies, focusing on neurology, oncology, and immunology. The Company's products addresses ...
May 16, 2012 at 14:13 | Source: Financial News Network Online
TYSABRI is marketed and distributed by Biogen Idec Inc. and Elan Corporation, plc. For full prescribing information, including boxed warning and important safety information, and more information about TYSABRI, please visit www.biogenidec.com or ...
May 26, 2012 at 17:28 | Source: Yahoo Finance